A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

NCT02508870 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Atezolizumab
DRUG: Azacitidine

Sponsor

Hoffmann-La Roche